У нас вы можете посмотреть бесплатно What is my first-choice drug for treating Glaucoma? - Café com Oftalmo или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
👁 In this week's Café com Oftalmo, we'll talk about how to choose the best drug to start glaucoma treatment on an individual basis, without making the mistake of always prescribing the same eye drops for all patients. ☕👁🗨 We'll talk about the potency of each class, therapeutic adherence, contraindications, and even when to consider SLT as the first option. I'll also explain why prostaglandin isn't always the best choice and what alternatives to use when it's not indicated. And an important update: unfortunately, Timoptol XE is being discontinued in Brazil and is already out of stock in some cities, which requires a new look at choosing the ideal beta-blocker. 👁 Do you want to have more security in the management of your glaucoma patients? Learn more about my online course, Glaucoma from Basic to Practical, by clicking here: http://www.glaucomaacademy.com.br/curso 👁 Glaucoma Academy - I help you improve and update your knowledge about glaucoma so that you can feel confident in managing your patients. I am Samantha Vasques, an ophthalmologist specializing in glaucoma and cataracts from Rio de Janeiro. I decided to combine my passion for teaching with my mission to combat blindness caused by glaucoma. I have over 10 years of experience teaching ophthalmology residents from various services in Rio de Janeiro, and now, through Glaucoma Academy, this content is available to you, ophthalmologists from any city in Brazil. 👁 Social media: Education for ophthalmologists - / glaucomaacademy Education for patients - / papoglaucoma Papo Glaucoma on Youtube - / @papoglaucoma 👁 Contact: [email protected]